Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm

Eli Lilly is so serious about becoming the leader in Alzheimer’s disease with donanemab that, last year, the Indianapolis Big Pharma challenged competitor Biogen by launching a head-to-head trial comparing their two therapies.

So what gives the company the confidence? Lilly CEO David Ricks knows it’ll win.